Intra-Cellular Therapies, Inc.
ITCI
株式のランク
#1689
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
株価
$131.87
最終同期: 2025-04-02
時価総額
$12.68B
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Intra-Cellular Therapies, Inc. (ITCI)
カテゴリー
Healthcare
Intra-Cellular Therapies, Inc.（ITCI）の利益
Dec 2024 時点の利益 TTM: $-74.20M
Intra-Cellular Therapies, Inc. の最新の財務報告によると、同社の現在の利益は $-74.20M です。2023 年には $-139.04M の利益を上げ、これは 2022 年の利益 $-256.25M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Intra-Cellular Therapies, Inc. の利益の推移（2013 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-74.20M | 0.00% |
| 2024 | $-74.20M | -46.63% |
| 2023 | $-139.04M | -45.74% |
| 2022 | $-256.25M | -9.81% |
| 2021 | $-284.12M | 25.17% |
| 2020 | $-226.99M | 53.66% |
| 2019 | $-147.72M | -4.77% |
| 2018 | $-155.13M | 56.96% |
| 2017 | $-98.83M | -14.33% |
| 2016 | $-115.36M | 10.09% |
| 2015 | $-104.79M | 241.45% |
| 2014 | $-30.69M | 14.30% |
| 2013 | $-26.85M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -2,478.01% |
IN
|
